Strategies to Improve Cataract Surgery Outcomes, Safety, and Patient Satisfaction (CME Monograph)

Activity Description and Purpose

Cataract surgery is recognized as one of the safest and most effective surgical procedures, yet preventing miosis, intraoperative and postoperative pain, and postoperative inflammation and cystoid macular edema is critical for optimizing the surgical experience and visual recovery of patients. The content of this activity is based on the proceedings of a live CME symposium that reviewed treatment strategies that can prevent or minimize these complications.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Apply evidence on intraoperative miosis control to manage patients undergoing cataract surgery
  • Evaluate recent data on pain management for patients undergoing cataract surgery
  • Examine strategies to prevent postoperative inflammation in cataract surgery
  • Identify strategies to optimize outcomes while reducing the risk of COVID-19 transmission in patients undergoing cataract surgery
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
04/01/2022
Course expires: 
04/30/2023
Cost:
$0.00

Faculty

Eric D. Donnenfeld, MD (Chair)
Clinical Professor of Ophthalmology
New York University Langone Medical Center
New York, New York
Founding Partner
Ophthalmic Consultants of Long Island and Connecticut
Garden City, New York
John A. Hovanesian, MD
Specialist in Cataract, Refractive, Cornea, and Pterygium Surgery
Harvard Eye Associates
Laguna Hills, California
Cathleen M. McCabe, MD
Cataract, Refractive, and Anterior Segment Surgery
Chief Medical Officer, Eye Health America
Medical Director, The Eye Associates
Bradenton, Florida
Elizabeth Yeu, MD
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Medical Director, Virginia Surgery Center
Cornea, Cataract, External Disease, and Refractive Surgery
Assistant Professor
Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, Virginia

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Eric D. Donnenfeld, MD, is a consultant for Allegro Ophthalmics, LLC, Allergan, Alcon, Avellino, Bausch & Lomb Incorporated, Beaver-Visitec International, BlephEx, CorneaGen, Covalent Laboratories, Dompé US, Inc, ELT Sight, EyePoint Pharmaceuticals, Foresight Labs, LLC, Glaukos Corporation, Ivantis Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Katena Products, Inc, LacriPen, LensGen, Mati Therapeutics, Inc, Merck & Co., Inc, Mimetogen Pharmaceuticals, Nanowafer, NovaBay Pharmaceuticals, Inc, Novaliq GmbH Germany, Novartis Pharmaceuticals Corporation, OcuHub LLC, Ocular Innovations, Oculis, Odyssey Medical, Inc, Omega Ophthalmics, Omeros Corporation, Oyster Point Pharma, Inc, Pfizer Inc, Physician Recommended Nutriceuticals, PogoTec, Rapid Pathogen Screening, Inc, Regener-Eyes, ReTEAR, Inc, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, TearScience, Thea Pharmaceuticals Limited, TLC Laser Eye Centers, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, Visus Therapeutics, and Zeiss; and has individual stocks or stock options in Avedro, Inc, CorneaGen, Covalent Laboratories, ELT Sight, EyePoint Pharmaceuticals, Glaukos Corporation, Ivantis Inc, LacriPen, LensGen, Mati Therapeutics, Inc, Mimetogen Pharmaceuticals, NovaBay Pharmaceuticals, Inc, OcuHub LLC, Ocular Innovations, Oculis, Orasis Pharmaceuticals, PogoTec, Rapid Pathogen Screening, Inc, Regener-Eyes, ReTEAR, Inc, Strathspey Crown, Surface, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Veracity, Versant Ventures, Visionary Ventures, and Visus Therapeutics.

John A. Hovanesian, MD, is a consultant for Abbott Medical Optics, AcuFocus, Inc, Aerie Pharmaceuticals, Inc, Alcon, Allegro Ophthalmics, LLC, Allergan, BlephEx, Eyedetec Medical, Glaukos Corporation, Guardion Health Sciences, Inc, IOP Ophthalmics, Ivantis Inc, Kala Pharmaceuticals, Katena Products, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, Sarentis Ophthalmics, Inc, Sensimed AG, Shire, TearLab Corporation, TearFilm Innovations Inc, Valeant, and Veracity Innovations LLC; is an advisory board member of Abbott Medical Optics, Aerie Pharmaceuticals, Inc, BlephEx, Cord LLC, Eyedetec Medical, Glaukos Corporation, Guardion Health Sciences, Inc, Ingenoeye LLC, IOP Ophthalmics, Ivantis Inc, Kala Pharmaceuticals, Katena Products, Inc, Ocular Therapeutix, Inc, Omeros Corporation, Shire, Sight Sciences, TearLab Corporation, Tear Film Innovations Inc, Valeant, and Veracity; is a contracted researcher for Abbott Medical Optics, AcuFocus, Inc, Aerie Pharmaceuticals, Inc, Alcon, Allergan, Cloudbreak Therapeutics, Cord LLC, Eyedetec Medical, Glaukos Corporation, Ingenoeye LLC, IOP Ophthalmics, Katena Products, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, Shire, TearFilm Innovations Inc, and Valeant; and has individual stocks or stock options in Alcon, Allegro Ophthalmics, Allergan, BlephEx, Eyedetec Medical, Glaukos Corporation, Guardion Health Sciences, Inc, Ingenoeye LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, RxSIGHT, Sarentis Ophthalmics, Inc, Sight Sciences, and TearFilm Innovations Inc.

Cathleen M. McCabe, MD, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, EyePoint Pharmaceuticals, Eyevance, Imprimis Pharmaceuticals, Inc, iSTAR Medical, Ivantis Inc, LENSAR, LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, Orasis Pharmaceuticals, Quidel Corporation, ScienceBased Health, Sight Sciences, Tarsus Pharmaceuticals, Inc, Visus Therapeutics, and Zeiss; is on the speakers bureau for Alcon, Allergan, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, Ivantis Inc, LENSAR, LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, and Sight Sciences; and is a contracted researcher for Alcon, Glaukos Corporation, Ivantis Inc, Ocular Therapeutix, Inc, Ora, Inc, Orasis Pharmaceuticals, and Sun Pharmaceutical Industries, Inc.

Elizabeth Yeu, MD, is a consultant for Alcon, Allergan, Avedro, Bausch & Lomb Incorporated, Beaver-Visitec International, BlephEx, Bruder Healthcare, CorneaGen, Dompé US, Inc, Expert Opinion, EyePoint Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, LENSAR, LLC, Merck & Co., Inc, Minosys Cellular Devices Inc, Novartis Pharmaceuticals Corporation, Ocular Science, Ocular Therapeutix, Inc, OCuSOFT Inc, Omeros Corporation, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharmaceuticals Limited, Topcon Medical Systems, Inc, Visus Therapeutics, and Zeiss; is on the speakers bureau for Glaukos Corporation; is a contracted researcher for Alcon, Bio-Tissue, Ocular Science, TearLab Corporation, and Topcon Medical Systems, Inc; and has individual stocks or stock options in BlephEx, CorneaGen, Ocular Science, Oyster Point Pharma, Inc, and Tarsus Pharmaceuticals, Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant financial relationships.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Medical Writer: Cheryl Guttman Krader has individual stocks or stock options in Johnson and Johnson Vision Care, Inc.

Accreditation Statement

 MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Omeros Corporation.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Omeros Corporation, EyeNet, or the American Academy of Ophthalmology.

This CME activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 254.2

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Clicking Register indicates that you have reviewed the CME information for this activity.